8-K: Simulations Plus Meets FY25 Guidance, Projects Low FY26 Growth

Simulations Plus announced preliminary fiscal year 2025 results, meeting revised guidance, and issued conservative fiscal year 2026 guidance amidst a challenging market.

Summary

• Simulations Plus reported preliminary fiscal year 2025 results, successfully meeting its revised guidance.
• Preliminary FY2025 revenue was $79.1 million, with 13% revenue growth, a 58% software mix, 28% adjusted EBITDA margin, and adjusted diluted EPS of $1.03.
• The company provided preliminary fiscal year 2026 guidance, projecting revenue between $79 million and $82 million.
• FY2026 revenue growth is estimated to be between 0% and 4%, with a software mix of 57% to 62%.
• Adjusted EBITDA margin for FY2026 is guided between 26% and 30%, and adjusted diluted EPS between $1.03 and $1.10.
• Management noted a challenging market environment due to uncertainty in funding, drug pricing, and tariffs affecting pharmaceutical and biotech clients.
• A new product vision was unveiled, focusing on accelerating software enhancements, deepening platform integration, and advancing AI capabilities.
• The recent launch of GastroPlus X.2 (GPX.2) with AI-powered tools on the S+ Cloud is the first step in a broader integrated Cloud and AI strategy.
• Full fourth quarter and fiscal year 2025 financial results are expected to be reported on December 1, 2025, along with the Annual Report on Form 10-K.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company met its revised FY2025 guidance and is strategically investing in AI and cloud, the FY2026 revenue growth guidance is quite low (0-4%), reflecting a challenging market environment. This indicates stability but limited immediate growth potential.

Positives

• Successfully met revised fiscal year 2025 guidance despite a challenging market environment.
• Unveiled a new product vision aimed at accelerating software enhancements, deepening platform integration, and advancing AI capabilities.
• Launched GastroPlus X.2 (GPX.2) with AI-powered tools on the S+ Cloud, marking a significant step in its Cloud and AI strategy.
• Plans to expand AI capabilities across other flagship platforms to enhance client productivity and data insights.

Negatives

• Operating in a challenging market environment characterized by uncertainty around funding, drug pricing, and tariffs.
• Fiscal year 2026 revenue growth guidance is low, ranging from 0% to 4%.
• Preliminary financial results are unaudited and subject to adjustment in the final audited financial statements.

Risks

• Substantial risks and uncertainties inherent in forward-looking statements.
• Known and unknown risks, uncertainties, and other factors could cause actual results to differ materially from projections.
• Effectiveness of the new operational structure.
• Ability to maintain competitive advantages in the market.
• Acceptance of new software and improved versions by customers.
• General economics of the pharmaceutical industry.
• Ability to finance future growth initiatives.
• Ability to attract and retain highly qualified technical staff.
• Adverse market conditions and macroeconomic factors.
• Maintaining a sustainable market for products and services.
• Ongoing uncertainty around funding, drug pricing, and tariffs affecting pharmaceutical and biotech clients.

Future Outlook

The company expects current challenging market conditions to remain stable and is issuing preliminary fiscal 2026 guidance based on this assumption. A new product vision is being unveiled to accelerate software enhancements, deepen platform integration, and advance AI capabilities, with plans to expand AI-powered tools across flagship platforms following the launch of GastroPlus X.2 (GPX.2) on the S+ Cloud.

Management Comments

• We expect to successfully meet our revised fiscal 2025 guidance despite operating in a challenging market environment shaped by ongoing uncertainty around funding, drug pricing, and tariffs affecting both our pharmaceutical and biotech clients.
• Looking ahead, we are issuing preliminary guidance for fiscal 2026 based on the assumption that current market conditions remain stable.
• As part of our ongoing commitment to innovation, we are excited to unveil our new product vision, which is designed to accelerate delivery of software enhancements, deepen platform integration, and advance our AI capabilities.
• The recent launch of GastroPlus X.2 (GPX.2) marks the debut of our AI-powered tools on the S+ Cloud—an important first step in our broader, integrated Cloud and AI strategy.
• Over the next year, we plan to expand these capabilities across our other flagship platforms, delivering greater value to our clients through enhanced productivity, richer data insights, and streamlined decision support.
• We look forward to sharing additional details when we report our fiscal 2025 results in December.

Industry Context

Simulations Plus operates in the biopharma sector, providing advanced software and consulting services. The challenging market environment, characterized by uncertainty in funding, drug pricing, and tariffs, reflects broader pressures on pharmaceutical and biotech clients. The company's strategic focus on AI and cloud integration aligns with a growing industry trend towards leveraging advanced technologies for drug discovery and development to enhance efficiency and data insights.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Will see preliminary FY2025 results that met revised guidance, but also a conservative FY2026 growth outlook, potentially impacting short-term stock performance. Long-term investors may view AI and cloud strategy positively.
• Employees: The focus on innovation and new product vision, particularly in AI and cloud, suggests continued investment in technology and potentially new opportunities.
• Customers (biopharma industry): Will benefit from accelerated software enhancements, deeper platform integration, and advanced AI capabilities, leading to enhanced productivity and richer data insights.
• Regulatory agencies: As a provider to regulatory agencies, continued innovation and robust solutions will support their work.

Next Steps

• Shawn O'Connor will participate in the KeyBanc Non-Deal Roadshow on October 28, 2025.
• Shawn O'Connor will participate in the Stephens Annual Investment Conference 2025 on November 19, 2025.
• Shawn O'Connor will participate in the BTIG Digital Health Forum on November 24, 2025.
• The company will report fourth quarter and fiscal 2025 financial results after market close on Monday, December 1, 2025.
• The Annual Report on Form 10-K for fiscal year 2025 is expected to be filed on December 1, 2025.
• Shawn O'Connor and Will Frederick will host a conference call and webcast on December 1, 2025, at 5:00 PM ET to discuss results and forward-looking information.
• Shawn O'Connor will participate in the TD Cowen 3rd Annual Diagnosing Tomorrow Conference on December 11, 2025.
• Expand AI capabilities across other flagship platforms over the next year.

Key Dates

Recommendation

The company successfully met its revised FY2025 guidance, which is a positive indicator of operational execution in a challenging market. However, the FY2026 revenue growth guidance of 0-4% is quite modest, suggesting limited near-term upside given the ongoing market uncertainties in funding, drug pricing, and tariffs. While the strategic focus on AI and cloud integration is a promising long-term initiative, its immediate financial impact is not yet clear. A 'hold' recommendation is appropriate for a seasoned investor, awaiting further clarity on the effectiveness of new product strategies and a potential improvement in market conditions before committing to a stronger position.

Keywords

Simulations Plus, SLP, Biopharma, Biosimulation, Cheminformatics, AI, Machine Learning, Drug Discovery, Drug Development, Financial Guidance, Preliminary Results, SEC Filing, Software, Consulting Services